• Accelerating TB vaccine Research & Development through partnership
  • TBVI TBVI TBVI
    • Home
    • About us
      • TBVI at a glance
      • Mission
      • Organisation
        • Governance Board
        • Advisory Committee
        • Steering Committee
        • Operational Office
        • Product and Clinical Development Team
        • Portfolio Management Committee
      • TBVI consortium
      • Key achievements and impact
      • Financials
      • Policies
    • What we do
      • Pipeline of vaccines
      • Research & Development
      • Services
    • How we work
      • Business model
      • Partnership
    • For partners
      • For researchers and vaccine developers
        • Partners pages
        • Access to services
      • MTBVAC in Newborns
        • Coordinator and partners
        • News and Publications
        • Communication tools
      • MTBVACN3
        • Work packages
        • Governance
        • The consortium and its partners
        • Publications and news
        • Acknowledgement
      • TBVAC2020
        • Word from the chair
        • TBVAC2020 project overview and achievements
        • TBVAC2020 project members
        • TBVAC2020 scientific publications
        • TBVAC2020 other publications
      • For funders
        • TBVI R&D priorities and funding opportunities
        • TBVI service provision and funding opportunities
        • Why invest in TBVI
    • News
    • Contact us:

    Archives

    Monthly Archive for: "October, 2017"
    Home / 2017 / October
      0
    By Cora Agterdenbosch
    In News Posted October 31, 2017

    Tuberculosis world’s top infectious killer

    UN health agency calls for political action to stop spread Read more:

    Read More
      0
    By Cora Agterdenbosch
    In News Posted October 24, 2017

    New International Vaccine R&D Network – “VALIDATE”

    The UK’s Medical Research Council (MRC) has awarded funds to Prof Helen McShane (University of Oxford) and Associate Prof Helen Fletcher (London School of Hygiene & Tropical Medicine) to set [...]

    Read More
      0
    By Cora Agterdenbosch
    In News Posted October 24, 2017

    Press release: MTBVAC – phase 2a

    The new Spanish tuberculosis vaccine MTBVAC has received 12 million euros to carry out Phase 2a trials in new-borns and in adults in South Africa. read the press release  

    Read More
      0
    By Cora Agterdenbosch
    In Events, News, Uncategorized Posted October 16, 2017

    TBVAC2020 review article now online

    TBVAC2020 (a European consortium of TB R&D partners led by TBVI and funded by the EC) gives an update on its progress towards the development of new, safe and affordable TB vaccines – [...]

    Read More
    Load More
    Menu
    • Home
    • About us
    • What we do
    • How we work
    • For researchers and vaccine developers
    • For funders
    • Pipeline of vaccines
    • News
    TuBerculosis Vaccine Initiative (TBVI)

    Runderweg 6
    8219 PK Lelystad
    The Netherlands
    Email: info@tbvi.eu
    Phone: +31 320 277 550

    © 2015 TuBerculosis Vaccine Initiative (TBVI) | ALL RIGHTS RESERVED | Disclaimer | Sitemap | Door Internetbureau Redkiwi

    Start typing and press Enter to search

    Cookies

    This website uses cookies that help the website function

    OK No